---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-26-000032"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:21:54.928016+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Travere's FILSPARI for FSGS without nephrotic syndrome, expanding label beyond IgAN

## Summary
- FDA approved FILSPARI (sparsentan) for FSGS without nephrotic syndrome in patients aged 8+, second indication.
- Addressable U.S. population estimated >30,000 individuals with FSGS without nephrotic syndrome.
- Phase 3 DUPLEX: 48% proteinuria reduction in non-nephrotic patients vs 27% irbesartan (p=0.0075).
- eGFR benefit: treatment difference 1.1 mL/min/1.73m2 at Week 108 favoring FILSPARI.
- Safety profile comparable to irbesartan, consistent with prior programs.

## SEC filing metadata
- accession: 0001438533-26-000032
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/0001438533-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-26-000032
- JSON: https://secwatch.observer/filing/0001438533-26-000032.json
- Plain text: https://secwatch.observer/filing/0001438533-26-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.